167 related articles for article (PubMed ID: 37149836)
41. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up.
Wu JQ; Feng HJ; Ouyang W; Sun YG; Chen P; Wang J; Xian JL; Huang LH
Nucl Med Commun; 2015 Aug; 36(8):819-26. PubMed ID: 25932534
[TBL] [Abstract][Full Text] [Related]
42. The Preventive Effect of Parotid Gland Massage on Salivary Gland Dysfunction During High-Dose Radioactive Iodine Therapy for Differentiated Thyroid Cancer: A Randomized Clinical Trial.
Son SH; Lee CH; Jung JH; Kim DH; Hong CM; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
Clin Nucl Med; 2019 Aug; 44(8):625-633. PubMed ID: 31274608
[TBL] [Abstract][Full Text] [Related]
43. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
[TBL] [Abstract][Full Text] [Related]
44. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E
J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401
[TBL] [Abstract][Full Text] [Related]
45. Prediction of the success of thyroid remnant ablation using preablative 99mTc pertechnetate scintigraphy and postablative dual 131I scintigraphy.
Jung JS; Lee SM; Kim SJ; Choi J; Han SW
Nucl Med Commun; 2015 Jan; 36(1):38-44. PubMed ID: 25299469
[TBL] [Abstract][Full Text] [Related]
46. Radioactive iodine and the salivary glands.
Mandel SJ; Mandel L
Thyroid; 2003 Mar; 13(3):265-71. PubMed ID: 12729475
[TBL] [Abstract][Full Text] [Related]
47. Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment.
Torun N; Muratli A; Serim BD; Ergulen A; Altun GD
Curr Med Imaging Rev; 2019; 15(4):395-404. PubMed ID: 31989909
[TBL] [Abstract][Full Text] [Related]
48. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up.
Baudin C; Bressand A; Buffet C; Menegaux F; Soret M; Lê AT; Cardon T; Broggio D; Bassinet C; Huet C; Armengol G; Richardson DB; Leenhardt L; Bernier MO; Lussey-Lepoutre C
Thyroid; 2023 Sep; 33(9):1100-1109. PubMed ID: 37300484
[No Abstract] [Full Text] [Related]
49. The evaluation of protective and mitigating effects of vitamin C against side effects induced by radioiodine therapy.
Jafari E; Alavi M; Zal F
Radiat Environ Biophys; 2018 Aug; 57(3):233-240. PubMed ID: 29860661
[TBL] [Abstract][Full Text] [Related]
50. Thyroid Patient Salivary Radioiodine Transit and Dysfunction Assessment Using Chewing Gums.
Okkalides D
Cancer Biother Radiopharm; 2016 Nov; 31(9):330-341. PubMed ID: 27831763
[TBL] [Abstract][Full Text] [Related]
51. Ultrasound Changes in Salivary Glands after Radioactive Iodine Treatment in Benign Diseases and Differentiated Cancer of Thyroid Glands in Consideration of Dose and Time Dependency.
Koch M; Fauck V; Sievert M; Mantsopoulos K; Iro H; Mueller S
Ultraschall Med; 2024 Jan; ():. PubMed ID: 38171382
[TBL] [Abstract][Full Text] [Related]
52. Ultrasonographic Features of Salivary Glands after Radioiodine Therapy in Patients with Thyroid Cancer.
Tsur N; Avishai G; Alkan U; Hod R; Shpitzer T; Bitton E; Gilat H
Laryngoscope; 2023 May; 133(5):1271-1275. PubMed ID: 36354236
[TBL] [Abstract][Full Text] [Related]
53. Incidence and risk factors for radioactive iodine-induced sialadenitis.
Sánchez Barrueco A; González Galán F; Alcalá Rueda I; Santillán Coello JM; Barrio Dorado MP; Villacampa Aubá JM; Escanciano Escanciano M; Llanos Jiménez L; Mahillo Fernández I; Cenjor Español C
Acta Otolaryngol; 2020 Nov; 140(11):959-962. PubMed ID: 32815758
[TBL] [Abstract][Full Text] [Related]
54. Salivary gland scintigraphy after radioiodine therapy.
Malpani BL; Samuel AM; Jaiswar RK
Nucl Med Commun; 1998 Feb; 19(2):183-4. PubMed ID: 9548203
[No Abstract] [Full Text] [Related]
55. A randomized controlled trial for the use of thymus honey in decreasing salivary gland damage following radioiodine therapy for thyroid cancer: research protocol.
Charalambous A; Frangos S; Talias M
J Adv Nurs; 2014 Jul; 70(7):1663-71. PubMed ID: 24256334
[TBL] [Abstract][Full Text] [Related]
56. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
Bohuslavizki KH; Klutmann S; Jenicke L; Kröger S; Buchert R; Mester J; Clausen M
Cancer Biother Radiopharm; 1999 Oct; 14(5):337-47. PubMed ID: 10850318
[TBL] [Abstract][Full Text] [Related]
57. [Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy (author's transl)].
Albrecht HH; Creutzig H
Rofo; 1976 Dec; 125(6):546-51. PubMed ID: 137852
[TBL] [Abstract][Full Text] [Related]
58. Semi-quantitative assessment of salivary gland function in patients with differentiated thyroid carcinoma after radioiodine-131 treatment.
Esfahani AF; Fallahi B; Olamaie R; Eftekhari M; Beiki D; Saghari M
Hell J Nucl Med; 2004; 7(3):206-9. PubMed ID: 15841302
[TBL] [Abstract][Full Text] [Related]
59. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Bleckmann C; Brenner W; Lassmann S; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Feb; 175(2):57-61. PubMed ID: 10065139
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study.
Cistaro A; Quartuccio N; Garganese MC; Villani MF; Altini C; Pizzoferro M; Piccardo A; Cabria M; Massollo M; Maghnie M; Campennì A; Siracusa M; Baldari S; Panareo S; Urso L; Bartolomei M; De Palma D; Grossi A; Mazzoletti A; Dondi F; Bertagna F; Giubbini R; Albano D
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1374-1385. PubMed ID: 34664092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
